Oramed Pharmaceuticals (ORMP) Current Assets (2011 - 2026)

Oramed Pharmaceuticals' Current Assets history runs 16 years deep, the most recent figure standing at $68.1 million for Q1 2026.

• Quarterly Current Assets fell 48.17% year-over-year to $68.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $68.1 million (down 48.17% YoY) and the FY2025 annual result came in at $133.3 million, down 6.95% from the prior year.
• Current Assets was $68.1 million for Q1 2026 at Oramed Pharmaceuticals, down from $133.3 million in the prior quarter.
• Across five years, Current Assets topped out at $177.1 million in Q1 2024 and bottomed at $68.1 million in Q1 2026.
• A 5-year average of $142.6 million and a median of $143.6 million in 2022 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2024 — Current Assets advanced 14.14% — and 2026, when it slumped 48.17%.
• Oramed Pharmaceuticals' Current Assets stood at $157.1 million in 2022, then climbed by 3.48% to $162.6 million in 2023, then decreased by 11.91% to $143.2 million in 2024, then fell by 6.95% to $133.3 million in 2025, then plunged by 48.86% to $68.1 million in 2026.
• Business Quant data shows ORMP's Current Assets at $68.1 million in Q1 2026, $133.3 million in Q4 2025, and $136.1 million in Q3 2025.